logo
Select company
Select metric
$ 9.86MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
40
Sector
77
Industry
91
History
93
$ 8.3Close
$ 6.41 - $ 16.8 52-Week Range
Ticker Information

Ticker

GYRE

Company Name

GYRE THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

GYRE THERAPEUTICS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

GYRE - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 2.85M$ 7M$ 9.86M
3/31/2025$ 2.43M$ 10.93M$ 13.36M
12/31/2024$ 2.22M$ 17.41M$ 19.63M
9/30/2024$ 2.96M$ -63.34M$ -60.39M
6/30/2024$ 2.37M$ -67.12M$ -64.75M
3/31/2024$ 1.95M$ -74.61M$ -72.66M
12/31/2023$ 1.43M$ -84.42M$ -82.99M
9/30/2023$ 14K$ -43.88M$ -43.86M
6/30/2023$ 54K$ -47.19M$ -47.13M
3/31/2023$ 120K$ 6.92M$ 7.04M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • GYRE THERAPEUTICS INC's latest trailing twelve months (TTM) EBITDA stands at $ -50.82M.
  • Over the past 5 years, GYRE THERAPEUTICS INC's average EBITDA has been $ -41.88M.
  • The median EBITDA for GYRE THERAPEUTICS INC during this period was $ -53.46M
  • GYRE THERAPEUTICS INC reached its highest EBITDA over the past 5 years at $ 19.63M.
  • The lowest EBITDA recorded by GYRE THERAPEUTICS INC in the same timeframe $ -87.64M

GYRE THERAPEUTICS INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
PHAT : PHATHOM PHARMACEUTICALS INC $ -256.75MNAGE : NIAGEN BIOSCIENCE INC $ 19.78MANAB : ANAPTYSBIO INC $ -130.11MTBPH : THERAVANCE BIOPHARMA INC $ 48.42MURGN : UROGEN PHARMA LTD $ -134.34MCRMD : CORMEDIX INC $ 52.25MNRIX : NURIX THERAPEUTICS INC $ -225.49MZVRA : ZEVRA THERAPEUTICS INC $ 36.45MKURA : KURA ONCOLOGY INC $ -192.46MSAGE : SAGE THERAPEUTICS INC $ -300.6M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for GYRE THERAPEUTICS INC is calculated as follows: EBIT [ $ -50.94M ] + DepAmor [ $ 127K ]
(=) EBITDA [ $ -50.82M ]

GYRE - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -87.64M

Minimum

Dec 31, 2021

$ 19.63M

Maximum

Dec 31, 2024

$ -41.88M

Average

$ -53.46M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M